English

Fourth quarter and full year report, 2024: A strong finish to the year

Report this content

Fourth quarter

  • Sales of SEK 959 (904) million, an increase of 6% in local currencies and 6% in SEK.
  • Sales per region, in local currencies was +10% in EMEA, +9% in Americas and -2% in APAC.
  • Sales per business area, in local currencies was +12% in Consumables, +9% in Technologies and 0% in Genetics.
  • Gross margin increased to 61.1% (56.9).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 337 (294) million, giving an EBITDA margin of 35.1% (32.5).
  • Operating cash flow increased to SEK 268 million (171).
  • Net income was SEK 139 (-4,179) million, resulting in earnings per share before dilution of SEK 1.03 (-30.86) and after dilution of SEK 1.02 (-30.86).
  • Helena Wennerström was appointed acting CFO of Vitrolife AB (publ) effective 3 December 2024.

Full year

  • Sales of SEK 3,609 (3,512) million, an increase of 4% in local currencies and 3% in SEK.
  • Sales per region, in local currencies was +7% in EMEA, +1% in Americas and +5% in APAC.
  • Sales per business area, in local currencies was +10% in Consumables, +16% in Technologies and -5% in Genetics.
  • Gross margin increased to 59.3% (56.3).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 1,225 (1,136) million, giving an EBITDA margin of 34.0% (32.3).
  • Operating cash flow increased to SEK 907 million (757).
  • Net income was SEK 514 (-3,851) million, resulting in earnings per share before dilution of SEK 3.79 (-28.44) and after dilution of SEK 3.78 (-28.44).

Dividend

  • The Board to propose to the Annual General Meeting a dividend of SEK 149 (135) million, corresponding to SEK 1.10 (1.00) per share.

Gothenburg, January 30, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 30-01-2025 08:00 CET.

Contact:
Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Subscribe

Documents & Links